Mizuho initiated coverage of Nurix Therapeutics (NRIX) with an Outperform rating and $24 price target Th company’s lead asset bexobrutideg is positioned to play a “significant role” in the treatment of chronic lymphocytic leukemia, the analyst tells investors in a research note. The firm believes the data to date supports a “clear path” towards accessing the $10B BTK degrader market. It projects $1.9B in risk-adjusted 2035 worldwide sales.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Promising Potential and Strategic Pipeline: A Buy Recommendation for Nurix Therapeutics
- Promising Clinical Results of NX-1607 Support Buy Rating for Nurix Therapeutics
- Nurix Therapeutics announces new clinical data from Phase 1a study NX-1607
- Nurix Therapeutics: Strong Cash Position and Upcoming Clinical Milestones Justify Buy Rating Despite Larger Net Loss
- Nurix Therapeutics price target lowered to $33 from $34 at H.C. Wainwright